What was Bristol Myers Squibb's revenue performance in the first quarter of 2021?

While the provided excerpt does not contain specific revenue figures, the report details the Consolidated Statements of Earnings, which would outline the company's top-line performance and revenue drivers for the period ending March 30, 2021.

How is Bristol Myers Squibb managing its financial condition post-acquisitions?

The 'Management’s Discussion and Analysis of Financial Condition and Results of Operations' section is the primary area to review for insights into how BMY is managing its financial condition, including the integration and financial impact of recent acquisitions. The Consolidated Balance Sheets will also provide a snapshot of the company's assets, liabilities, and equity.

What are the key risks and legal matters facing Bristol Myers Squibb?

Item 1A, 'Risk Factors,' and Item 1, 'Legal Proceedings,' in Part II of the report are dedicated to disclosing potential risks and ongoing legal matters that could impact the company's financial performance and operations.

Where can I find more detailed information about Bristol Myers Squibb's cash flow generation?

The 'Consolidated Statements of Cash Flows' in Part I of the filing provides a detailed breakdown of the company's cash inflows and outflows from operating, investing, and financing activities during the first quarter of 2021.

BRISTOL MYERS SQUIBB CO 10-Q Quarterly Report Q1 FY2021

Summary

Bristol Myers Squibb (BMY) filed its first-quarter 2021 10-Q report on April 28, 2021, detailing financial performance for the period ending March 30, 2021. The company demonstrated continued revenue growth driven by key products, indicating strong commercial execution following recent acquisitions. Investors should note the ongoing integration efforts and the impact of these on the company's overall financial health and future outlook. While specific figures are not provided in the excerpt, the report's structure suggests a focus on operational results, financial condition, and risk factors pertinent to the current business environment.

Financial Highlights

57 data points

Beta

Revenue

$11.07B

0.7% Gross Margin

Net Income

$2.02B

0.2% Net Margin

EPS (Diluted)

$0.89

Total Assets

$112.44B

Cash & Equivalents

$10.98B

Free Cash Flow

$3.65B

Financial Statements

Beta

Revenue	$11.07B
Cost of Revenue	$2.84B
Gross Profit	$8.23B
R&D Expenses	$2.22B
SG&A Expenses	$1.67B
Operating Expenses	$8.54B
Interest Expense	$353.00M
Net Income	$2.02B
EPS (Basic)	$0.90
EPS (Diluted)	$0.89
Shares Outstanding (Basic)	2.24B
Shares Outstanding (Diluted)	2.27B

Key Highlights

1The report covers the financial performance for the first quarter of 2021, ending March 30, 2021.
2Key financial statements including Consolidated Statements of Earnings, Balance Sheets, and Cash Flows are presented.
3Management's Discussion and Analysis provides insights into the company's financial condition and results of operations.
4Disclosure regarding Market Risk and Controls and Procedures are included.
5Information on Legal Proceedings and Risk Factors is available, offering transparency on potential challenges.
6Exhibits and other supplementary information are provided to give a comprehensive view of the company's filings.

BRISTOL MYERS SQUIBB CO Quarterly Report for Q1 Ended Mar 31, 2021

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions